MRD in WM: its potential in guiding treatment decisions and as a surrogate endpoint in trials

MRD as an endpoint in clinical trialsПодробнее

MRD tests and surrogate endpoint testingПодробнее

Opinion: value of MRD as an endpoint in hem-onc clinical trialsПодробнее

Using MRD as an endpoint in clinical trialsПодробнее

MRD in multiple myeloma: prognosis, a clinical trial endpoint, and guiding treatment decisionsПодробнее

Standardizing MRD techniques after FDA approval as a surrogate endpoint in myeloma trialsПодробнее

How can MRD negativity be used as an endpoint in clinical trials?Подробнее

MRD as a surrogate endpoint for AML therapyПодробнее

Using MRD to guide treatment decisions in the clinicПодробнее

The importance of using MRD to guide treatment decisions in ALLПодробнее

ASH 2023 | Minimal Residual Disease (MRD) measurement in myelomaПодробнее

Is MRD a new surrogate endpointПодробнее

The possibility of using MRD as a surrogate endpoint for PFS and OS in myeloma clinical trialsПодробнее

The value of MRD as an early endpoint in multiple myeloma clinical trialsПодробнее

The Benefit of Detecting Minimal Residual Disease in MMПодробнее

MRD as a surrogate endpoint: what remains for FDA approval?Подробнее

Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 2Подробнее

Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 1Подробнее